Berhyanda Limited made an offer to acquire 26% stake in Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) for INR 32.8 billion on December 26, 2022. Under the terms of transaction, Berhyanda will acquire 66.2 million shares of Suven at INR 495 Per share. Advent International has confirmed that it had adequate resources and made financial arrangements to fund the transaction. In related transaction, Advent International Corporation entered into a share purchase agreement to acquire 50.1% stake in Suven Pharmaceuticals Limited from Jasti Family for INR 63 billion on December 26, 2022. Berhyanda Limited is ultimately controlled by Advent International. Post completion of offer and agreement, Advent will acquire sole control of Suven. The Transaction is subject to approval from regulatory & statutory approval which includes approval from RBI, CCI, Department from Pharmaceuticals and other related institutions Offer is not subject to minimum level of acceptance. As of April 20, 2023, Competition Commission of India (CCI) has approved the acquisition of Suven Pharmaceuticals Limited by Berhyanda Limited. Tender offer will commence from February 16 till March 1, 2023. The Union Cabinet on September 13, 2023, approved INR 9,589 crore foreign direct investment (FDI) proposal by a Cyprus-based firm in Suven Pharmaceuticals. Kotak Mahindra Capital Company Limited acted as manager to offer and KFin Technologies Limited acted as registrar on behalf of Advent International Corporation. Shishir Vayttaden and Bhargav Joshi of Cyril Amarchand Mangaldas acted as legal advisor in transaction.

Berhyanda Limited completed the acquisition of 0.001% stake in Suven Pharmaceuticals Limited (NSEI:SUVENPHAR) for INR 1.3 million on November 3, 2023.